High Prevalence of TROP2 Expression Identifies EBV-Positive Gastric Cancer as a Candidate for TROP2-Directed Antibody–Drug Conjugates
This study demonstrates that TROP2 is highly expressed in the vast majority of EBV-positive gastric cancers, identifying this molecular subtype as a promising candidate for TROP2-directed antibody-drug conjugates, particularly for patients who do not respond to immune checkpoint inhibitors.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Stomach cancer remains one of the most formidable challenges in modern medicine, ranking as the fifth most common cancer worldwide and a leading cause of cancer-related death. For patients with advanced disease, current treatments often offer only a few extra months of life, highlighting a desperate need for new strategies. Scientists have learned that stomach cancer is not a single disease but a collection of different types, each driven by unique genetic changes. One specific type, caused by the Epstein-Barr virus, behaves differently from the rest; it tends to occur in younger men and, despite its aggressive molecular features, often responds well to immunotherapy because the body's immune system recognizes it as a foreign invader. However, not every patient with this viral type of cancer benefits from immune treatments, leaving a gap for other therapies. A promising new class of drugs, known as antibody-drug conjugates, works like a guided missile, seeking out a specific protein on the surface of cancer cells to deliver a toxic payload directly to the tumor. This protein, called TROP2, has been identified as a target in many cancers, but until now, no one knew if it was present in the viral type of stomach cancer, which would determine if these new drugs could work for these specific patients.
Researchers at the University of Cologne set out to solve this puzzle by examining tissue samples from hundreds of patients who had undergone surgery for stomach cancer. They focused on a large group of 525 individuals, sorting them into four distinct molecular categories based on the genetic makeup of their tumors. Using a standard laboratory technique that stains tissue samples to make proteins visible under a microscope, the team looked specifically for the presence of TROP2 on the surface of the cancer cells. They measured how much of this protein was there, assigning a score to each sample to determine if the protein was absent, present in low amounts, or present in high amounts. This approach allowed them to see if the viral type of stomach cancer shared the same protein profile as the other types or if it stood apart.
The investigation revealed a striking difference between the viral tumors and the others. While many of the non-viral stomach cancers lacked the TROP2 protein entirely or had very little of it, the tumors driven by the Epstein-Barr virus were almost universally positive for it. In fact, nearly all of the viral tumors, about 96 percent, showed clear signs of the protein, with many displaying high levels. Only a tiny fraction, roughly 3.7 percent, had no TROP2 at all. In contrast, other subtypes of stomach cancer showed much higher rates of missing the protein, with some groups having up to 36 percent of tumors that lacked it completely. This finding suggests that the viral subtype is uniquely suited for treatment with these guided missile drugs, as the target they seek is almost always there.
The researchers also looked at how the presence of this protein affected patient survival. In the broader group of all stomach cancer patients, those with high levels of TROP2 tended to have shorter survival times, though this difference did not reach a level of statistical certainty in this specific study. However, when they focused solely on the patients with the viral type of cancer, the amount of TROP2 did not seem to change the outcome; survival rates were similar whether the protein was low or high. This indicates that while the protein might be a marker of aggression in other forms of the disease, its primary importance in the viral type lies in its availability as a target for therapy rather than as a predictor of how the disease will naturally progress.
These results provide a strong reason to test these targeted drugs in patients with the viral form of stomach cancer, especially for those who do not respond to immunotherapy. Since the vast majority of these tumors carry the TROP2 protein, they are likely candidates for treatment with antibody-drug conjugates, which could offer a new lifeline when other options fail. The study does not claim that these drugs will cure the disease, but it establishes a clear biological basis for trying them. By identifying a specific group of patients who almost certainly have the right target, the researchers have moved the conversation from speculation to a concrete plan for clinical trials. The next step is to see if delivering a toxic drug directly to these TROP2-rich cells can improve survival in a controlled medical setting, turning a molecular observation into a tangible treatment option for a difficult disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.